In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential

Oncotarget

Volumn 5, Issue 19, 2014, Pages 8869-8878

  Raffeiner, Philipp ^a   Röck, Ruth ^a   Schraffl, Andrea ^a   Hartl, Markus ^a   Hart, Jonathan R ^b   Janda, Kim D ^b   Vogt, Peter K ^b   Stefan, Eduard ^a   Bister, Klaus ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Biosensor; Cancer; Protein protein interactions; Small molecule inhibitors; Transcription factor

Indexed keywords

BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; MAX PROTEIN; MYC PROTEIN; PROTEIN L MYC; PROTEIN MXD1; PROTEIN V MYC; PYRIDINE; RENILLA LUCIFERIN 2 MONOOXYGENASE; TRANSCRIPTION FACTOR; TUMOR PROTEIN; UNCLASSIFIED DRUG; 10074-G5; 5-(4-ETHYLBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE; KJ-PYR-9; MNT PROTEIN, HUMAN; MXD1 PROTEIN, HUMAN; OXADIAZOLE DERIVATIVE; PROTEIN BINDING; PYRIDINE DERIVATIVE; REPRESSOR PROTEIN; THIAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; CARCINOGENICITY; CELL PROLIFERATION; EMBRYO; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR DYNAMICS; MOLECULAR LIBRARY; MUTATIONAL ANALYSIS; NONHUMAN; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; TUMOR CELL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HEK293 CELL LINE; METABOLISM; NEOPLASM; PROTEIN MULTIMERIZATION; TUMOR CELL LINE;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CELL PROLIFERATION; HEK293 CELLS; HUMANS; LUCIFERASES, RENILLA; NEOPLASMS; OXADIAZOLES; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS C-MYC; PYRIDINES; REPRESSOR PROTEINS; THIAZOLES;

EID: 84910070397     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2588     Document Type: Article

References (44)

1. Duesberg PH, Bister K, Vogt PK. The RNA of avian acute leukemia virus MC29. Proc. Natl. Acad. Sci. USA. 1977; 74:4320-4.
2. Vogt PK. Retroviral oncogenes: a historical primer. Nat. Rev. Cancer. 2012; 12:639-48.
3. BisterK. MC29 avian myelocytomatosis virus. Brenner's Encyclopedia of Genetics, eds Maloy S, Hughes K (Academic Press, San Diego), 2nd Ed. 2013; Vol 4: 330-2.
4. Bister K, Hayman MJ, Vogt PK. Defectiveness of avian myelocytomatosis virus MC29: Isolation of long-term nonproducer cultures and analysis of virus-specific polypeptide synthesis. Virology. 1977; 82:431-48.
5. Blackwood EM, Eisenman RN. Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science. 1991; 251:1211-7.
6. Eisenman RN. Deconstructing Myc. Genes Dev. 2001; 15:2023-30.
7. Dang CV. MYC on the path to cancer. Cell. 2012; 149:22-35.
8. Conacci-Sorrell M, McFerrin L, Eisenman RN. An overview of MYC and its interactome. Cold Spring Harb. Perspect. Med. 2014; 4:a014357.
9. Lin CY, Lovén J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012; 151:56-67.
10. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, Wang R, Green DR, Tessarollo L, Casellas R, Zhao K, Levens D. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012; 151:68-79.
11. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev. 2008; 22:2755-66.
12. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl. Acad. Sci. USA. 1982; 79:7824-7.
13. Fieber W, Schneider ML, Matt T, Kräutler B, Konrat R, Bister K. Structure, function, and dynamics of the dimerization and DNA binding domain of oncogenic transcription factor v-Myc. J. Mol. Biol. 2001; 307:1395-410.
14. Nero TL, Morton CJ, Holien JK, Wielens J, Parker MW. Oncogenic protein interfaces: small molecules, big challenges. Nat. Rev. Cancer. 2014; 14:248-62.
15. Berg T, Cohen SB, Desharnais J, Sonderegger C, Maslyar DJ, Goldberg J, Boger DL, Vogt PK. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc. Natl. Acad. Sci. USA. 2002; 99:3830-5.
16. Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene. 2003; 22:6151-9.
17. Prochownik EV, Vogt PK. Therapeutic targeting of Myc. Genes Cancer. 2010; 1:650-9.
18. Hart JR, Garner AL, Yu J, Ito Y, Sun M, Ueno L, Rhee JK, Baksh MM, Stefan E, Hartl M, Bister K, Vogt PK, Janda KD. Inhibitor of MYC identified in a Kröhnke pyridine library. Proc. Natl. Acad. Sci. USA. 2014; 111:12556-61.
19. Michnick SW, Ear PH, Manderson EN, Remy I, Stefan E. Universal strategies in research and drug discovery based on protein-fragment complementation assays. Nat. Rev. Drug. Discov. 2007; 6:569-82.
20. Stefan E, Aquin S, Berger N, Landry CR, Nyfeler B, Bouvier M, Michnick SW. Quantification of dynamic protein complexes using Renilla luciferase fragment complementation applied to protein kinase A activities in vivo. Proc. Natl. Acad. Sci. USA. 2007; 104:16916-21.
21. Taylor SS, Ilouz R, Zhang P, Kornev AP. Assembly of allosteric macromolecular switches: lessons from PKA. Nat. Rev. Mol. Cell. Biol. 2012; 13:646-58.
22. Nair SK, Burley SK. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 2003; 112:193-205.
23. Ferré-D'Amaré AR, Prendergast GC, Ziff EB, Burley SK. Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain. Nature. 1993; 363:38-45.
24. Stefan E, Malleshaiah MK, Breton B, Ear PH, Bachmann V, Beyermann M, Bouvier M, Michnick SW. PKA regulatory subunits mediate synergy among conserved G-protein-coupled receptor cascades. Nat. Commun. 2011; 2:598.
25. Bachmann VA, Riml A, Huber RG, Baillie GS, Liedl KR, Valovka T, Stefan E. Reciprocal regulation of PKA and Rac signaling. Proc. Natl. Acad. Sci. USA. 2013; 110:8531-6.
26. Grinberg AV, Hu CD, Kerppola TK. Visualization of Myc/Max/Mad family dimers and the competition for dimerization in living cells. Mol. Cell. Biol. 2004; 24:4294-308.
27. Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S. Promotion of direct reprogramming by transformation-deficient Myc. Proc. Natl. Acad. Sci. USA. 2010; 107:14152-7.
28. Ayer DE, Kretzner L, Eisenman RN. Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 1993; 72:211-22.
29. Huang Z, Traugh JA, Bishop JM. Negative control of the Myc protein by the stress-responsive kinase Pak2. Mol. Cell. Biol. 2004; 24:1582-94.
30. Vervoorts J, Luscher-Firzlaff J, Luscher B. The ins and outs of MYC regulation by posttranslational mechanisms. J. Biol. Chem. 2006; 281:34725-9.
31. Valovka T, Schönfeld M, Raffeiner P, Breuker K, Dunzendorfer-Matt T, Hartl M, Bister K. Transcriptional control of DNA replication licensing by Myc. Sci. Rep. 2013; 3:3444.
32. Moscovici C, Moscovici MG, Jimenez H, Lai MM, Hayman MJ, Vogt PK. Continuous tissue culture cell lines derived from chemically induced tumors of Japanese quail. Cell 1977; 11:95-103.
33. Oberst C, Hartl M, Weiskirchen R, Bister K. Conditional cell transformation by doxycycline-controlled expression of the MC29 v-myc allele. Virology 1999; 253:193-207.
34. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18:3004-16.
35. Reiter F, Hartl M, Karagiannidis AI, Bister K. WS5, a direct target of oncogenic transcription factor Myc, is related to human melanoma glycoprotein genes and has oncogenic potential. Oncogene 2007; 26:1769-79.
36. Hartl M, Nist A, Khan MI, Valovka T, Bister K. Inhibition of Myc-induced cell transformation by brain acid-soluble protein 1 (BASP1). Proc. Natl. Acad. Sci. USA. 2009; 106:5604-9.
37. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013; 339:1546-58.
38. Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug. Discov. 2004; 3:1001-10.
39. Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat. Rev. Cancer 2014; 14:455-67.
40. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 2004; 3:301-17.
41. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 2013; 19:202-8.
42. Touzeau C, Dousset C, Le Gouill S, Sampath D, Leverson JD, Souers AJ, Maïga S, Béné MC, Moreau P, Pellat-Deceunynck C, Amiot M. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014; 28:210-2.
43. Kakkola L, Denisova OV, Tynell J, Viiliäinen J, Ysenbaert T, Matos RC, Nagaraj A, Ohman T, Kuivanen S, Paavilainen H, Feng L, Yadav B, Julkunen I, et al. Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice. Cell Death Dis. 2013; 4:e742.
44. Follis AV, Hammoudeh DI, Wang H, Prochownik EV, Metallo SJ. Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem. Biol. 2008; 15:1149-55.